JN.1
SARS-CoV-2 JN.1 Variant
JN.1 emerged as a descendant of BA.2.86 with additional mutations conferring transmission advantages.
Quick Facts
Transmissibility
Enhanced transmissibility over parent BA.2.86
Vaccine Evasion
Moderate to high immune evasion
Global Prevalence
Rapidly increasing (2024-2025)
Symptoms & Signs
Common Symptoms
Distinctive Features
Prevention & Treatment
Prevention Strategies
Treatment Options
Current antivirals and therapeutics remain effective
Key Mutations
L455S in spike proteinGlobal Surveillance
Key Research Findings
Rapid global spread in late 2023 and 2024
Generally maintains mild disease profile
Influenced 2024-2025 vaccine composition
Demonstrates continued viral evolution
High-Risk Groups
Related Variants
Omicron BA.5
BA.5 was the dominant Omicron subvariant during summer 2022, characterized by increased transmissibi...
Omicron XBB
XBB is a recombinant variant combining genetic material from two BA.2 sublineages, showing enhanced ...
BA.2.86
BA.2.86 represents a highly divergent Omicron subvariant with numerous spike protein mutations....
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult with qualified healthcare providers for diagnosis, treatment, and medical guidance. Information last updated: 2025-06-20.